Cullinan Therapeutics (CGEM) to Release Quarterly Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.80) per share and revenue of $5.5560 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 9, 2026 at 9:30 AM ET.

Cullinan Therapeutics Stock Up 2.1%

Shares of CGEM stock opened at $12.44 on Thursday. The firm has a market cap of $734.96 million, a price-to-earnings ratio of -3.76 and a beta of -0.09. Cullinan Therapeutics has a 52-week low of $5.68 and a 52-week high of $13.43. The company’s 50 day moving average is $11.20 and its 200 day moving average is $9.08.

Analysts Set New Price Targets

Several research firms have recently commented on CGEM. Wedbush boosted their price target on Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. HC Wainwright boosted their target price on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Citigroup initiated coverage on shares of Cullinan Therapeutics in a report on Tuesday. They issued a “buy” rating and a $33.00 price target on the stock. BTIG Research lifted their price objective on shares of Cullinan Therapeutics from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Cullinan Therapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $29.33.

Insider Activity at Cullinan Therapeutics

In other news, insider Jacquelyn L. Sumer sold 3,480 shares of Cullinan Therapeutics stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $9.67, for a total transaction of $33,651.60. Following the completion of the sale, the insider directly owned 135,432 shares in the company, valued at approximately $1,309,627.44. The trade was a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jennifer Michaelson sold 4,000 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $12.30, for a total transaction of $49,200.00. Following the sale, the insider directly owned 128,635 shares in the company, valued at $1,582,210.50. This trade represents a 3.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 33,836 shares of company stock worth $361,087 in the last quarter. 7.16% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cullinan Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CGEM. Schonfeld Strategic Advisors LLC purchased a new position in Cullinan Therapeutics during the 4th quarter worth approximately $172,000. AlphaCentric Advisors LLC purchased a new stake in shares of Cullinan Therapeutics in the fourth quarter worth about $197,000. Fox Run Management L.L.C. boosted its position in Cullinan Therapeutics by 36.6% in the 4th quarter. Fox Run Management L.L.C. now owns 21,204 shares of the company’s stock worth $219,000 after purchasing an additional 5,676 shares in the last quarter. Caption Management LLC grew its stake in shares of Cullinan Therapeutics by 107.0% during the 3rd quarter. Caption Management LLC now owns 28,389 shares of the company’s stock worth $168,000 after purchasing an additional 435,062 shares during the period. Finally, Magnetar Financial LLC purchased a new position in Cullinan Therapeutics in the third quarter valued at $156,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.